Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Sushmita M. Chanda

Key Takeaway: Sushmita M. Chanda, Ph.D., has been appointed as the Executive Vice President and Chief Development Officer at the company. She brings a wealth of experience from her previous roles at Alios BioPharma and F. Hoffman-La Roche. Dr. Chanda is a Diplomate of the American Board of Toxicology and has a solid educational foundation in Toxicology and Pharmacology.
Price reaction · baseline $12.125 (2024-08-02 close) · hit after-hours · 3 other ALGS headline(s) in the window, move may be shared
day 0 close
-5.2%
day 1
-7.8%
day 3 · peak
+12.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Chanda has extensive experience in pharmaceutical development.
  • She has held leadership roles in reputable companies.
  • Her educational background is strong, with a Ph.D. in Toxicology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

Sushmita M. Chanda, Ph.D., serves as our Executive Vice President and Chief Development Officer. Prior to joining the Company, from February 2010 to July 2018, Dr. Chanda served as Vice President, Preclinical Development at Alios BioPharma, Inc., which was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company. Dr. Chanda was at F. Hoffman-La Roche Ltd, a multinational healthcare company, from 2000 to 2010, where over the years she served in various roles of increasing responsibilities, including Senior Director and Head of Nonclinical Safety. Prior to Roche, she was a toxicologist at Sugen Inc., a pharmaceutical company (bought by Pfizer), from May 1998 to January 2000. Dr. Chanda is a Diplomate of American Board of Toxicology (DABT). Dr. Chanda received her B.S. and M.S. from Birla Institute of Technology, Mesra, India and a Ph.D. in Toxicology and Pharmacology from the University of Louisiana at Monroe. She completed her post-doctoral fellowship in Toxicology at USEPA through the University of North Carolina at Chapel Hill.

Frequently Asked Questions

What is Dr. Sushmita Chanda's role at ALGS?

Dr. Sushmita Chanda serves as the Executive Vice President and Chief Development Officer.

Where did Dr. Chanda work before ALGS?

She previously worked at Alios BioPharma and F. Hoffman-La Roche.

What qualifications does Dr. Chanda hold?

Dr. Chanda has a Ph.D. in Toxicology and is a Diplomate of the American Board of Toxicology.

What experience does Dr. Chanda have in the industry?

She has over 20 years of experience in various roles within pharmaceutical companies.

Last updated: Aug 2, 2024